Legend Biotech - American Depositary Shares (LEGN) closed at $17.50 on November 13, 2026, down 5.6% from the previous close, on volume of 2,856,510 shares (30-day average 2,214,833).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 4, 2026 | Diagonal Put Spread | 18-Dec-26 : 21-Jan-2827.5 : 22.5 P | 1,430 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Legend Biotech Earnings Call Signals Strong CARVYKTI Momentum
TipRanks (Sat, 14-Nov 10:05 PM ET)
TipRanks (Wed, 11-Nov 8:40 AM ET)
TipRanks (Wed, 11-Nov 8:30 AM ET)
Analysts’ Top Healthcare Picks: Protalix (PLX), Legend Biotech (LEGN)
TipRanks (Wed, 11-Nov 6:50 AM ET)
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN) and Legend Biotech (LEGN)
TipRanks (Wed, 11-Nov 4:01 AM ET)
Legend Biotech GAAP EPS of -$0.13 misses by $0.14, revenue of $359.5M misses by $0.41M
Seeking Alpha News (Tue, 10-Nov 7:03 AM ET)
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
Globe Newswire (Tue, 10-Nov 7:00 AM ET)
Gabelli Releases Agenda for 8th Annual Healthcare Symposium
Globe Newswire (Mon, 9-Nov 8:00 AM ET)
Market Chameleon (Wed, 4-Nov 4:37 AM ET)
Globe Newswire (Wed, 4-Nov 9:00 AM ET)
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
Legend Biotech - American Depositary Shares trades on the NASDAQ stock market under the symbol LEGN.
As of November 13, 2026, LEGN stock price declined to $17.50 with 2,856,510 million shares trading.
LEGN has a beta of 0.70, meaning it tends to be less sensitive to market movements. LEGN has a correlation of 0.01 to the broad based SPY ETF.
LEGN has a market cap of $3.40 billion. This is considered a Mid Cap stock.
Last quarter Legend Biotech - American Depositary Shares reported $360 million in Revenue and $.14 earnings per share. This fell short of revenue expectation by $-409,248 and exceeded earnings estimates by $.13.
In the last 3 years, LEGN traded as high as $70.13 and as low as $16.24.
The top ETF exchange traded funds that LEGN belongs to (by Net Assets): IBB, IEMG, PBE, CANC, PINK.
LEGN has underperformed the market in the last year with a price return of -43.6% while the SPY ETF gained +13.4%. LEGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -13.7% and -19.1%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
LEGN support price is $17.71 and resistance is $19.37 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LEGN shares will trade within this expected range on the day.
